Evandro de Azambuja, MD, PhD of the Institut Jules Bordet, Brussels, Belgium, evaluates the results of the PHranceSCa study (NCT03674112), which aimed to determine patient satisfaction with subcutaneous administration of a fixed-dose combination of pertuzumab and trastuzumab in comparison to intravenous infusion in HER2+ early breast cancer patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
